The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-01

Study Completion Date

2021-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis

NCT02526303

Liver Cirrhosis Portal Vein Thrombosis Anticoagulation

WITHDRAWN NA

Splenic Embolization for Portal Hypertension

NCT03532750

Portal Hypertension

WITHDRAWN NA

Hematological Disorders in EHPVO Patients

NCT07108023

Extrahepatic Portal Vein Obstruction (EHPVO) Thrombophilia Myeloproliferative Neoplasms (MPN) +5 more

NOT_YET_RECRUITING

Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis

NCT01595672

Acute Pancreatitis

UNKNOWN NA

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

NCT05304455

Cirrhosis Splenectomy Venous Thrombosis +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery. Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension and acute pulmonary embolism or deep vein thrombosis is reported in the anamnesis of 75% of those with chronic thromboembolic disease. Therefore, the etiology of the disease is not clear. Altought many studies are done, especially the role of inflamation is emhasised underlie the disease.

Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension.

Matrix metalloprotinase enzymes are known to play a role in atherosclerosis. This research will investigate whether there is atherosclerosis together with inflamattion in the background of chronic thromboembolic hypertension.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Thromboembolic Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PATİENT GROUP(GROUP 1)

This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.

matrix metalloproteinase enzymes 2 and 9

Intervention Type OTHER

concentration of matrix metalloproteinase 2 and 9 enzymes

CONTROL GROUP(GROUP 2)

This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.

matrix metalloproteinase enzymes 2 and 9

Intervention Type OTHER

concentration of matrix metalloproteinase 2 and 9 enzymes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

matrix metalloproteinase enzymes 2 and 9

concentration of matrix metalloproteinase 2 and 9 enzymes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Despite 3 months of anticoagulation therapy
* mean pulmonary arterial pressure \> 20 mmHg
* pulmonary vasculary resistance \> 3 wood
* pulmonary capillary wedge pressure \< 15 mmHg
* perfusion defect in ventilation perfusion scintigraphy
* pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions

Exclusion Criteria

* Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery
* Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No